At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 738 enrolled
Drug / intervention
secukinumab 150 mg +1 moredrug
Likely dose
secukinumab 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
In Brief
A Phase 3 clinical trial evaluating secukinumab 150 mg and placebo to secukinumab 150 mg for Moderate to Severe Plaque-type Psoriasis. Completed, enrolled 738 participants across 88 sites in 12 countries.
Detailed Summary
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Plaque-type Psoriasis
CountriesArgentina, Canada, Colombia, Estonia, Iceland, Israel, Japan, Latvia, Lithuania, Mexico, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJun 2011
Primary CompletionApr 2013
TodayJul 2026
First PostedJun 3, 2011
Enrollment StartJun 1, 2011
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.1 years ago
Interventions
secukinumab 150 mgdrug
secukinumab (AIN457) 150mg or 300mg subcutaneous
placebo to secukinumab 150 mgdrug
Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous